Sangamo Therapeutics, Inc. (SGMO) Balance Sheet

The consistent decline in total assets suggests that the company is consuming its foundational resources to fund ongoing R&D, leaving little room for operational pivots. This downward trajectory in asset value appears to correlate with the lack of commercial product sales, indicating that the business model remains entirely dependent on external capital injections.

A current ratio below unity is a clear indicator of liquidity strain, particularly for a firm with no commercial revenue to offset its high burn rate. Investors should monitor this metric closely, as the narrowing gap between cash reserves and liabilities suggests that the company's operational runway is effectively exhausted.

The transition to negative equity suggests that the company's cumulative losses, totaling -$1.7B in retained earnings, have completely eroded the value attributable to shareholders. This structural impairment warrants further investigation into the company's long-term solvency and the potential for future restructuring or significant equity dilution.

While the absolute debt level may appear modest, the lack of positive equity and the absence of operating cash flow make even this amount a significant burden. The company's reliance on debt in a pre-revenue state appears to be a necessity-driven strategy that further complicates its path to financial stability.